2024 - Going Beyond ATS/ERS 2019 Guidelines for Your Respiratory Clinical Trials

Join this insightful webinar in which the expert speakers will explore the evolution of data quality assessments in respiratory drug development. Historically, adherence to enforced spirometry standards from the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines has been the acceptable measure of high-quality data. However, despite refinements made in 2019 to address limitations in the historical standards, inconsistencies and aberrant treatment effects remain a persistent challenge, raising concerns over data accuracy.
Clario, a leader in clinical research technology, has been initiating a more focused approach to ensure respiratory data accuracy within clinical trials. By introducing data plausibility as an additional quality step, data anomalies can be identified early on, thus mitigating risks and accelerating drug development timelines.
In this webinar, the speakers will explore the following topics:
Limitations of traditional adherence to ATS/ERS enforced spirometry standards
Role of data plausibility in enhancing data accuracy and reliability
Impact of data plausibility on identifying inconsistencies and aberrant treatment effects
Potential of embedding data plausibility within AI functionality to drive high-quality data
How improved data quality can accelerate drug development, reduce costs and enable better development decisions for personalized medicine
Register for this webinar today to gain valuable insights into the future of data quality assessment in respiratory drug development and learn how you can leverage these advancements to drive success in your respiratory clinical trials.
Keywords: Respiratory, Data Science, Chronic Lung Diseases, AI, Artificial Intelligence, Pulmonary Disease, Therapeutic Areas, Spirometry, Lung Function, Clinical Trials, Clinical Data, Respiratory Disease, COPD, CRO, Clinical Research, Asthma, Lung Disease, Drug Development